Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Intensity Therapeutics is a clinical-stage biotechnology company developing INT230-6, a proprietary intratumoral cancer therapy designed to kill tumor cells and activate systemic immune responses. The company is advancing Phase 2 trials in breast cancer and other solid tumors, with no commercial revenue and operations funded through equity raises. Stock performance reflects clinical trial progress, regulatory milestones, and cash runway visibility.
Intensity operates as a clinical-stage biotech with no current revenue, burning approximately $15-20M annually on R&D and clinical trials. The business model depends on advancing INT230-6 through Phase 2/3 trials to demonstrate efficacy in solid tumors, then either partnering with large pharma for commercialization (upfront payments, milestones, royalties) or pursuing independent FDA approval and commercialization. Competitive advantage lies in the dual-mechanism approach (direct tumor cell kill plus immune activation) and intratumoral delivery avoiding systemic toxicity. Value creation hinges entirely on clinical data readouts and regulatory progress.
INT230-6 Phase 2 clinical trial data releases (objective response rates, progression-free survival)
FDA regulatory interactions and trial design agreements (Special Protocol Assessment, breakthrough designation)
Partnership or licensing deal announcements with major pharmaceutical companies
Equity financing announcements and cash runway updates (dilution concerns)
Competitive landscape changes in immuno-oncology and intratumoral therapy space
Binary clinical trial risk - Phase 2/3 failure would likely render equity worthless given single-asset focus
Regulatory approval uncertainty - FDA may require additional trials or reject approval despite positive data
Competitive pressure from established immuno-oncology players (Merck, BMS, Roche) with superior resources and market access
Large pharma intratumoral therapy programs (Amgen's IMLYGIC, Johnson & Johnson's talimogene) could establish market dominance
Systemic immunotherapy combinations (checkpoint inhibitors plus targeted therapy) may prove superior to intratumoral approaches
Severe cash burn ($15-20M annually) with no revenue requires continuous equity financing creating dilution risk
Current market cap near cash value suggests high probability of significant dilution or unfavorable partnership terms
89% one-year stock decline indicates potential going-concern risk if unable to access capital markets
low - Clinical trial timelines and FDA regulatory processes are largely insulated from GDP fluctuations. However, severe recessions can impact ability to raise capital and pharmaceutical company M&A activity. Investor risk appetite for speculative biotech is cyclical.
Rising rates negatively impact valuation multiples for pre-revenue biotechs as future cash flows are discounted more heavily. Higher rates also increase cost of capital for future financings and reduce investor appetite for high-risk, long-duration assets. The company's current 3.60x current ratio provides near-term liquidity buffer, but future equity raises become more dilutive in high-rate environments.
Minimal direct credit exposure given negligible debt (0.02 D/E ratio). However, credit market conditions affect biotech sector financing availability. Tight credit markets can force companies to accept unfavorable partnership terms or conduct dilutive equity raises.
growth - Attracts high-risk, high-reward biotech specialists and retail investors seeking asymmetric upside from clinical trial success. The 89% one-year decline and -144.5% FCF yield indicate this is purely speculative with no value or income characteristics. Institutional ownership likely minimal given micro-cap status and binary risk profile.
high - Clinical-stage single-asset biotechs exhibit extreme volatility around data catalysts. The -48% three-month return demonstrates typical price swings. Beta likely exceeds 2.0x relative to broader market, with intraday moves of 20-50% common on trial updates.
